Shots: The company has submitted MAA for Omburtamab to EMA for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma The company continues to advance the Omburtamab program addressing […]readmore
Tags : Omburtamab
Shots: EMA has agreed to the Y-mAbs’ proposed Pediatric Investigation Plan (“PIP”) for Omburtamab which follows EMA’s Pediatric Committee’s positive opinion The PIP approval allows Y-mAbs to file MAA of […]readmore